Ruikang Pharmaceutical Net profit of 1.008 billion last year | Layout of advanced medical device R&D production
Medical Network April 27 hearing Ruikang Pharmaceutical Announcements, Quotes, Reviews, Financial Statements) Released the 2017 annual report on the evening of April 25. During the reporting period, the company realized operating revenue of 23.294 billion yuan, an increase of 49.14% over the same period of last year; Attributable to the parent company The net profit was 1.008 billion yuan, an increase of 70.66% over the same period of last year.
Ruikang Pharmaceutical also issued a quarterly report for 2018. In the first quarter of 2018, it achieved operating revenue of 7.129 billion yuan, an increase of 43.2% over the same period of the previous year; net profit attributable to the parent company was 280.3 million yuan, released on the same date in the evening of April 25th. Annual report In the report period, the company realized operating income of 23.294 billion yuan, an increase of 49.14% over the same period of the previous year; net profit attributable to the parent company was 1.008 billion yuan, an increase of 70.66% over the same period of last year.
Ruikang Pharmaceutical also released its first quarterly report in 2018. In the first quarter of 2018, it achieved operating revenue of 7.129 billion yuan, an increase of 43.2% over the same period of the previous year; net profit attributable to the parent company was 280.3 million yuan, which was calculated on the same basis (excluding 2017Q1 changes in accounting estimates). After the one-time influencing factor), the year-on-year increase was 53.84%.
Ruikang Pharmaceutical Co., Ltd. stated that the growth of the company's revenue and profit was mainly due to the completion of the nationwide marketing network layout and the rapid growth of the medical device business. The year 2018 was the year when the company established the nationwide marketing network and was also the year of endogenous integration. The layout of '31 provincial platforms + 10 core business lines' will be fully completed, and its subsidiaries will be fully integrated into the SAP information system to enhance the business value, optimize the accounts receivable and cash flow management.
It is reported that Ruikang Pharmaceutical was established in 2004 and mainly established direct sales networks for medical institutions and retail channels. Its main business segments include: pharmaceuticals, medical equipment and consumables, medical logistics services, mobile medical information services, and medical industry third-party logistics. Chinese medicine, etc. The data shows that since the company was listed, the compound revenue growth rate has reached 40%, and the compounded growth rate of net profit attributable to the parent company has exceeded 50% since listing.
In recent years, the pace of mergers and reorganizations in the pharmaceutical distribution industry has accelerated, and the degree of industry concentration has further increased. Large-scale pharmaceutical business enterprise Both accelerated the pace of mergers and acquisitions. The establishment of a marketing network throughout the country through mergers and acquisitions has also become an important strategy of Ruikang Pharmaceutical. Ruikang Pharmaceuticals stated that the company has deeply integrated internal and external resources in the past two years, through the 'M&A+Partner' mechanism. Screening joined Rui Kang's operating partners to replicate the 'Rikang Model' and the company's efficient management system in Shandong Province.
In addition, Ruikang Pharmaceuticals stated that the company initially chose the 'direct sales business model', which is highly consistent with the current 'two-vote system' policy of medical reform. It is supplied from upstream pharmaceutical industry suppliers to commercial companies, and then supplied by commercial companies. hospital , pharmacy and other terminals, there are no other circulation links in the middle.
At present, Ruikang Pharmaceuticals has established nationwide direct sales channels in 31 provinces (municipalities, autonomous regions), and established business relationships with more than 30,000 medical institutions throughout the country. In Shandong market, the company has public hospitals above designated size, and grassroots medical institutions. The coverage rate was over 98% and 96%, respectively.
It is worth mentioning that the annual report shows that in the territory of Ruikang's pharmaceutical business, the proportion of medical device sales revenue to operating income has increased year by year. drug The price level has been declining year by year. The growth in the total sales volume of the pharmaceutical circulation market has slowed down. Correspondingly, medical equipment and consumables have maintained a high growth rate. The demand for medical device distribution and promotion business is very strong, with many varieties and professionalism. With high demands and rapid innovation, the gross margin level is higher. Currently, it is in a stage of rapid development. The data shows that the current annual growth rate of the device circulation is about 23%. The pharmaceutical circulation has entered a steady development stage with an annual growth rate of about 12%.
Since entering equipment circulation business in 2013, Ruikang medicine In 2017, the sales scale reached 7.333 billion yuan. In the past three years, the revenue from this sector was 1.051 billion yuan, 2.899 billion yuan and 7.333 billion yuan respectively, accounting for 10.77%, 18.56%, and 31.48% of the operating revenue respectively. Said that the company's major shareholders have advanced in the layout medical instruments The R&D and production plan will introduce some advanced international products and technologies into the country when conditions are ripe.
